Interestingly, due to its erythroid modulating properties, sirolimus is currently being tested in a clinical trial on transfusion-dependent beta-thalassemia patients (THALA-RAP, NCT04247750). This evidence concerns the gene LRPAP1 and Beta-thalassemia.